Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002826627 | SCV003599494 | uncertain significance | Inborn genetic diseases | 2022-01-26 | criteria provided, single submitter | clinical testing | The c.1862A>G (p.K621R) alteration is located in exon 16 (coding exon 15) of the CNOT1 gene. This alteration results from a A to G substitution at nucleotide position 1862, causing the lysine (K) at amino acid position 621 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Pittsburgh Clinical Genomics Laboratory, |
RCV004784112 | SCV005397293 | uncertain significance | Vissers-Bodmer syndrome | 2021-06-29 | criteria provided, single submitter | clinical testing | This sequence variant is a single nucleotide substitution (A>G) which results in a lysine to arginine amino acid change at residue 621 in the CNOT1 protein. This variant has not previously been reported in individuals with CNOT1-related disease, to our knowledge. This variant is rare in the gnomAD control population database (6/272260 alleles or 0.002%). Bioinformatic tools predict that this variant would be damaging, and the Lys621 residue is conserved in all the vertebrate species examined. Functiol studies testing the effect of this variant on protein structure or function have not been performed, to our knowledge. At this time, there is insufficient evidence to determine if this variant is pathogenic or benign. Therefore, we consider this to be a variant of uncertain significance. ACMG Criteria: PM2, PP3 |